Abstract
Tumors deficient in DNA mismatch repair are known to display increased susceptibility to immune checkpoint inhibitors due to accumulation of DNA damage and increased neoantigen load. This suggests that deficiency in the BRCA-related DNA repair mechanism may also be a surrogate marker for immunotherapy response. The aim of this study was to examine the efficacy of the immune checkpoint inhibitor, nivolumab, in women with BRCA gene mutations and recurrent müllerian cancer. This retrospective case series followed six BRCA carriers who received nivolumab monotherapy (3.0 mg/kg, intravenous, day 1 and 15, every 4 weeks) as salvage therapy for recurrent epithelial ovarian (n = 5) and fallopian tubal (n = 1) cancers. Toxicity, treatment response, and survival were examined. Median age was 57 (range 51-64). BRCA1 and 2 mutations were equally distributed. All had high-grade serous histology, and all but one had advanced-stage disease at initial diagnosis. The majority had platinum-resistant disease (n = 4). All received salvage therapy prior to nivolumab therapy (median 3 lines), including PARP inhibitors (n = 3). The median number of nivolumab treatment cycles was 9, including 2 women receiving 18 cycles. Three women developed nivoluma...Continue Reading
Citations
Sep 25, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tatyana V GorodnovaEvgeny N Imyanitov
Oct 28, 2019·Oncoimmunology·Jing-Jing WangKaren K Chan
Apr 26, 2019·PloS One·Wei Xiong Wen, Chee-Onn Leong
Jul 20, 2019·Journal of Telemedicine and Telecare·Xiaoshi Yang, Carrie L Kovarik
Feb 23, 2019·International Journal of Molecular Sciences·Marco GreppiEmanuela Marcenaro
Mar 12, 2020·Diagnostics·Fulvio BorellaDionyssios Katsaros
Sep 15, 2020·JCO Precision Oncology·Ying L LiuDmitriy Zamarin
Nov 5, 2020·Antioxidants & Redox Signaling·Congying PuMin Huang
Jan 6, 2021·ESMO Open·S ByeonS T Kim
Nov 25, 2018·Gynecologic Oncology·Julia L BolandDmitriy Zamarin
Apr 10, 2021·Nature Cancer·Robert M SamsteinNadeem Riaz
Aug 6, 2019·Clinical Genitourinary Cancer·Yana BeulqueBenoit Beuselinck
Jun 3, 2021·Cancers·Sandra van WilpeNiven Mehra
Aug 10, 2021·World Journal of Clinical Oncology·Evgeny Imyanitov, Anna Sokolenko
Aug 28, 2021·Current Oncology·Lisa KingetBenoit Beuselinck
Aug 30, 2021·Hereditary Cancer in Clinical Practice·Evgeny N Imyanitov
Sep 9, 2021·Immunotherapy·Pauline RochefortChristelle de la Fouchardiere